MoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabThere’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a Share XMoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabhttps://pharmaphorum.com/news/moonlake-launches-licensing-in-merck-kgaas-cosentyx-challenger-sonelokimab/
Avillion/Merck psoriasis nanobody hits the mark in phase 2UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Share XAvillion/Merck psoriasis nanobody hits the mark in phase 2https://pharmaphorum.com/news/avillion-merck-psoriasis-nanobody-hits-the-mark-in-phase-2/
GSK’s big-ticket cancer alliance with Merck KGaA stumbles againMerck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a Share XGSK’s big-ticket cancer alliance with Merck KGaA stumbles againhttps://pharmaphorum.com/news/gsks-big-ticket-cancer-alliance-with-merck-kgaa-hits-another-hurdle/
Merck KGaA offloads failed MEK programme to startup Day OneUS biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s Share XMerck KGaA offloads failed MEK programme to startup Day Onehttps://pharmaphorum.com/news/merck-kgaa-offloads-failed-mek-programme-to-startup-day-one/
COVID-19 increased demands on carers’ wellbeing, study findsCOVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, Share XCOVID-19 increased demands on carers’ wellbeing, study findshttps://pharmaphorum.com/news/covid-19-increased-demands-on-informal-carers-wellbeing-study-finds/
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenancePfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor Share XMerck, Pfizer get EU nod for Bavencio as bladder cancer maintenancehttps://pharmaphorum.com/news/merck-pfizer-get-eu-nod-for-bavencio-as-bladder-cancer-maintenance/
GSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialGlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after Share XGSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialhttps://pharmaphorum.com/news/gsk-merck-cos-hopeful-bintrafusp-alfa-fails-in-key-lung-cancer-trial/
Merck KGaA signs DNA damage response cancer deal with Artios PharmaGermany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel Share XMerck KGaA signs DNA damage response cancer deal with Artios Pharmahttps://pharmaphorum.com/news/merck-kgaa-signs-dna-damage-response-cancer-deal-with-artios-pharma/
Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancerThe Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including Share XScotland backs Merck/Pfizer’s Bavencio combo for kidney cancerhttps://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/
